FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979743318> ?p ?o ?g. }

• W2979743318 endingPage "vi100" @default.
• W2979743318 startingPage "vi99" @default.
• W2979743318 abstract "Abstract Background Irinotecan is a key drug for advanced gastric cancer (AGC). We previously reported that patients with UGT1A1 single heterozygous (SH) had significantly high frequency of severe hematological adverse events (AEs) compared to patients with UGT1A1 wild type (WT) in irinotecan monotherapy for AGC. However, the difference of initial dose and relative dose intensity (RDI) of irinotecan between UGT1A1 WT and SH might affect those results. Therefore, we compared between UGT1A1 SH and WT regarding the clinical outcomes of the fixed dose irinotecan monotherapy for AGC. Methods We retrospectively analyzed the clinical data of patients who received initial fixed dose irinotecan (150mg/m2, bi-weekly) in the multi-institutional retrospective study. 106 eligible patients were registered from 8 centers in Japan. Result The number of patients with UGT1A1 WT/SH were 62 and 38, respectively. In WT/SH patients, performance status 0/1/≥2 was 20/40/2 and 11/23/4, treatment line 2nd/3rd or later was 27/35 and 18/20, HER2 positive/negative 17/45 and 8/30, respectively. In WT/SH patients, median PFS was 3.2 and 3.3 months (HR = 1.137, P = 0.543) and median OS was 10.4 and 7.3 months (HR = 0.734, P = 0.184). In WT/SH patients, median treatment cycle was 6 and 4 (P = 0.973), and RDI was 0.85 vs 0.84(P = 0.915), respectively. Hematological AEs were observed in 82.2% and 92.1% (P = 0.138), severe hematological AEs (≥G3) were 35.4% and 63.1%(P = 0.006). Non-hematological AEs were 88.7% and 86.8%(P = 0.507), severe non-hematological AEs (≥G3) were 6.6% and 15.8% (P = 0.122), respectively. Severe AEs in more than 5% patients were leukopenia (11.3% and 15.8%), neutropenia (14.5% and 31.6%), anemia (21.0% and 23.7%), and anorexia (1.6% and 10.5%). Conclusion UGT1A1 SH patients who received initial fixed dose Irinotecan had high frequency of severe hematological AE compared to WT patients. However, there was no significant difference in efficacy of Irinotecan monotherapy in each group." @default.
• W2979743318 created "2019-10-18" @default.
• W2979743318 creator A5001876291 @default.
• W2979743318 creator A5014225991 @default.
• W2979743318 creator A5023876278 @default.
• W2979743318 creator A5025185461 @default.
• W2979743318 creator A5025447515 @default.
• W2979743318 creator A5026656732 @default.
• W2979743318 creator A5029924703 @default.
• W2979743318 creator A5039798934 @default.
• W2979743318 creator A5045916689 @default.
• W2979743318 creator A5047830005 @default.
• W2979743318 creator A5048421476 @default.
• W2979743318 creator A5053746933 @default.
• W2979743318 creator A5054182211 @default.
• W2979743318 creator A5056456991 @default.
• W2979743318 creator A5073532961 @default.
• W2979743318 creator A5076120991 @default.
• W2979743318 creator A5076417403 @default.
• W2979743318 creator A5080229788 @default.
• W2979743318 date "2019-10-01" @default.
• W2979743318 modified "2023-09-27" @default.
• W2979743318 title "The impact of UGT1A1 single-hetero regarding the toxicity of fixed dose irinotecan therapy for advanced gastric cancer" @default.
• W2979743318 doi "https://doi.org/10.1093/annonc/mdz338.041" @default.
• W2979743318 hasPublicationYear "2019" @default.
• W2979743318 type Work @default.
• W2979743318 sameAs 2979743318 @default.
• W2979743318 citedByCount "0" @default.
• W2979743318 crossrefType "journal-article" @default.
• W2979743318 hasAuthorship W2979743318A5001876291 @default.
• W2979743318 hasAuthorship W2979743318A5014225991 @default.
• W2979743318 hasAuthorship W2979743318A5023876278 @default.
• W2979743318 hasAuthorship W2979743318A5025185461 @default.
• W2979743318 hasAuthorship W2979743318A5025447515 @default.
• W2979743318 hasAuthorship W2979743318A5026656732 @default.
• W2979743318 hasAuthorship W2979743318A5029924703 @default.
• W2979743318 hasAuthorship W2979743318A5039798934 @default.
• W2979743318 hasAuthorship W2979743318A5045916689 @default.
• W2979743318 hasAuthorship W2979743318A5047830005 @default.
• W2979743318 hasAuthorship W2979743318A5048421476 @default.
• W2979743318 hasAuthorship W2979743318A5053746933 @default.
• W2979743318 hasAuthorship W2979743318A5054182211 @default.
• W2979743318 hasAuthorship W2979743318A5056456991 @default.
• W2979743318 hasAuthorship W2979743318A5073532961 @default.
• W2979743318 hasAuthorship W2979743318A5076120991 @default.
• W2979743318 hasAuthorship W2979743318A5076417403 @default.
• W2979743318 hasAuthorship W2979743318A5080229788 @default.
• W2979743318 hasBestOaLocation W29797433181 @default.
• W2979743318 hasConcept C121608353 @default.
• W2979743318 hasConcept C126322002 @default.
• W2979743318 hasConcept C143998085 @default.
• W2979743318 hasConcept C2780259306 @default.
• W2979743318 hasConcept C29730261 @default.
• W2979743318 hasConcept C526805850 @default.
• W2979743318 hasConcept C71924100 @default.
• W2979743318 hasConceptScore W2979743318C121608353 @default.
• W2979743318 hasConceptScore W2979743318C126322002 @default.
• W2979743318 hasConceptScore W2979743318C143998085 @default.
• W2979743318 hasConceptScore W2979743318C2780259306 @default.
• W2979743318 hasConceptScore W2979743318C29730261 @default.
• W2979743318 hasConceptScore W2979743318C526805850 @default.
• W2979743318 hasConceptScore W2979743318C71924100 @default.
• W2979743318 hasLocation W29797433181 @default.
• W2979743318 hasOpenAccess W2979743318 @default.
• W2979743318 hasPrimaryLocation W29797433181 @default.
• W2979743318 hasRelatedWork W1976604498 @default.
• W2979743318 hasRelatedWork W2027385411 @default.
• W2979743318 hasRelatedWork W2090004228 @default.
• W2979743318 hasRelatedWork W2138903976 @default.
• W2979743318 hasRelatedWork W2171919716 @default.
• W2979743318 hasRelatedWork W2408896420 @default.
• W2979743318 hasRelatedWork W2418638721 @default.
• W2979743318 hasRelatedWork W2469879407 @default.
• W2979743318 hasRelatedWork W2789695363 @default.
• W2979743318 hasRelatedWork W2809072147 @default.
• W2979743318 hasVolume "30" @default.
• W2979743318 isParatext "false" @default.
• W2979743318 isRetracted "false" @default.
• W2979743318 magId "2979743318" @default.
• W2979743318 workType "article" @default.